Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG

Journal of Pharmacological and Toxicological Methods

Volumn 67, Issue 1, 2013, Pages 33-44

  Gillie, Daniel J ^a   Novick, Steven J ^a   Donovan, Brian T ^a   Payne, Lisa A ^a   Townsend, Claire ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Electrophysiology; HERG; Ion channel; IonWorks Barracuda; KCNH2; Methods

Indexed keywords

ASTEMIZOLE; POTASSIUM CHANNEL HERG; QUINIDINE; TERFENADINE;

ANIMAL CELL; ARTICLE; AUTOMATION; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; INTERMETHOD COMPARISON; ION EXCHANGE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PROCESS DEVELOPMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPRODUCIBILITY; STABLE EXPRESSION; VOLTAGE CLAMP;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS;

EID: 84873059490     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.10.002     Document Type: Article

References (62)

1. Analytical Methods Committee Robust statistics - How not to reject outliers, Part 1. Basic concepts. Analyst 1989, 114:1693-1697.
2. Bischoff U., Schmidt C., Netzer R., Pongs O. Effects of fluoroquinolones on HERG currents. European Journal of Pharmacology 2000, 406:341-343.
3. Bridgland-Taylor M.H., Hargreaves A.C., Easter A., Orme A., Henthorn D.C., Ding M., et al. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. Journal of Pharmacological and Toxicological Methods 2006, 54:189-199.
4. + current in cardiac myocytes by dofetilide. Journal of Pharmacology and Experimental Therapeutics 1992, 262:809-817.
5. + channels by cultivation at reduced temperature. BMC Biotechnology 2007, 7:93.
6. + channels. Journal of Pharmacological Sciences 2004, 95:311-319.
7. Kr channel regulation through 14-3-3 epsilon. Human Molecular Genetics 2006, 15:2888-2902.
8. De Ponti F., Poluzzi E., Montanaro N. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience. European Journal of Clinical Pharmacology 2000, 56:1-18.
9. Donovan B.T., Bakshi T., Galbraith S.E., Nixon C.J., Payne L.A., Martens S.F. Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and NaV1.5 blockade. Journal of Pharmacological and Toxicological Methods 2011, 64:269-276.
10. Drolet B., Zhang S., Deschenes D., Rail J., Nadeau S., Zhou Z., et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. Journal of Cardiovascular Electrophysiology 1999, 10:1597-1604.
11. Dubin A.E., Nasser N., Rohrbacher J., Hermans A.N., Marrannes R., Grantham C., et al. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. Journal of Biomolecular Screening 2005, 10:168-181.
12. Finkel A., Wittel A., Yang N., Handran S., Hughes J., Costantin J. Population patch clamp improves data consistency and success rates in the measurement of ionic currents. Journal of Biomolecular Screening 2006, 11:488-496.
13. Golden A.P., Li N., Chen Q., Lee T., Nevill T., Cao X., et al. IonFlux: A microfluidic patch clamp system evaluated with human ether-a-go-go related gene channel physiology and pharmacology. Assay and Drug Development Technologies 2011, 9:608-619.
14. Guo L., Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. Journal of Pharmacological and Toxicological Methods 2005, 52:123-135.
15. Heylen L., Van Assouw H., Beerden I., Fonteyn I., Van de Vyver O., De Dlerck K., et al. Society for Biomolecular Screening [On-line] Available:. https://pharmacology.ricerca.com/CatalogJa/Pdf/HighThroughput.pdf.
16. Horn R., Marty A. Muscarinic activation of ionic currents measured by a new whole-cell recording method. Journal of General Physiology 1988, 92:145-159.
17. International Conference on Harmonization (ICH) The nonclinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals S7B 2005, Ref Type: Online Source.
18. 2+. Evidence for two distinct voltage sensors. Journal of General Physiology 1999, 113:565-580.
19. Kirsch G.E., Trepakova E.S., Brimecombe J.C., Sidach S.S., Erickson H.D., Kochan M.C., et al. Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern. Journal of Pharmacological and Toxicological Methods 2004, 50:93-101.
20. Kongsamut S., Kang J., Chen X.L., Roehr J., Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European Journal of Pharmacology 2002, 450:37-41.
21. Korsgaard M.P., Strobaek D., Christophersen P. Automated planar electrode electrophysiology in drug discovery: Examples of the use of QPatch in basic characterization and high content screening on Na(v), K(Ca)2.3, and K(v)11.1 channels. Combinatorial Chemistry & High Throughput Screening 2009, 12:51-63.
22. Kutchinsky J., Friis S., Asmild M., Taboryski R., Pedersen S., Vestergaard R.K., et al. Characterization of potassium channel modulators with QPatch automated patch-clamp technology: System characteristics and performance. Assay and Drug Development Technologies 2003, 1:685-693.
23. Lacerda A.E., Kramer J., Shen K.Z., Thomas D., Brown A.M. Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. European Heart Journal Supplements 2001, 3:K23-K30.
24. Luo T., Luo A., Liu M., Liu X. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656. Anesthesia and Analgesia 2008, 106:1161-1170.
25. Ly J.Q., Shyy G., Misner D.L. Assessing hERG channel inhibition using PatchXpress. Clinics in Laboratory Medicine 2007, 27:201-208.
26. Mannikko R., Overend G., Perrey C., Gavaghan C.L., Valentin J.P., Morten J., et al. Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel. British Journal of Pharmacology 2010, 159:102-114.
27. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. Journal of Cardiovascular Pharmacology 2004, 43:369-379.
28. Mathes C., Friis S., Finley M., Liu Y. QPatch: The missing link between HTS and ion channel drug discovery. Combinatorial Chemistry & High Throughput Screening 2009, 12:78-95.
29. McPate M., Lilley S., Gosling M., Friis S., Jacobsen R.B., Tranter P. Evaluation of the QPatch HT and HTX systems as methods for ion channel screening. Biophysical Journal 2010, 98(3):340a. (Ref Type: Abstract).
30. Milnes J.T., Dempsey C.E., Ridley J.M., Crociani O., Arcangeli A., Hancox J.C., et al. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Letters 2003, 547:20-26.
31. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:12329-12333.
32. Mo Z.L., Faxel T., Yang Y.S., Gallavan R., Messing D., Bahinski A. Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress. Journal of Pharmacological and Toxicological Methods 2009, 60:39-44.
33. + channel by the gastrointestinal prokinetic agent cisapride. American Journal of Physiology 1997, 273:H2534-H2538.
34. Novick S., Chiswell K., Peterson J. A Bayesian approach to show assay equivalence with replicate measurements over a specified response range. Statistics in Biopharmaceutical Research 2012, 4:102-117.
35. Pearlstein R.A., Vaz R.J., Kang J., Chen X.L., Preobrazhenskaya M., Shchekotikhin A.E., et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorganic & Medicinal Chemistry Letters 2003, 13:1829-1835.
36. + channel. A model for bad behavior. Journal of Medicinal Chemistry 2003, 46:2017-2022.
37. Perrin M.J., Kuchel P.W., Campbell T.J., Vandenberg J.I. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels. Molecular Pharmacology 2008, 74:1443-1452.
38. Polonchuk L. Toward a new gold standard for early safety: Automated temperature-controlled hERG test on the PatchLiner. Frontiers in Pharmacology 2012, 3:3.
39. Qu Y., Schnier P., Zanon R., Vargas H.M. hERG potency estimates based upon dose solution analysis: What have we learned?. Journal of Pharmacological and Toxicological Methods 2011, 64:251-257.
40. Rae J., Cooper K., Gates P., Watsky M. Low access resistance perforated patch recordings using amphotericin B. Journal of Neuroscience Methods 1991, 37:15-26.
41. + channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. British Journal of Pharmacology 2006, 149:481-489.
42. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58:32-45.
43. Kr potassium channel. Cell 1995, 81:299-307.
44. Shimizu W., Horie M., Ohno S., Takenaka K., Yamaguchi M., Shimizu M., et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: Multicenter study in Japan. Journal of the American College of Cardiology 2004, 44:117-125.
45. Smith P.L., Baukrowitz T., Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996, 379:833-836.
46. Snyders D.J., Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Molecular Pharmacology 1996, 49:949-955.
47. Tao H., Santa A.D., Guia A., Huang M., Ligutti J., Walker G., et al. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay and Drug Development Technologies 2004, 2:497-506.
48. Teschemacher A.G., Seward E.P., Hancox J.C., Witchel H.J. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. British Journal of Pharmacology 1999, 128:479-485.
49. Tie H., Walker B.D., Singleton C.B., Valenzuela S.M., Bursill J.A., Wyse K.R., et al. Inhibition of HERG potassium channels by the antimalarial agent halofantrine. British Journal of Pharmacology 2000, 130:1967-1975.
50. Tsujimae K., Suzuki S., Yamada M., Kurachi Y. Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. European Journal of Pharmacology 2004, 493:29-40.
51. Walker B.D., Singleton C.B., Bursill J.A., Wyse K.R., Valenzuela S.M., Qiu M.R., et al. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: Affinity for open and inactivated states. British Journal of Pharmacology 1999, 128:444-450.
52. Walker B.D., Valenzuela S.M., Singleton C.B., Tie H., Bursill J.A., Wyse K.R., et al. Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate. British Journal of Pharmacology 1999, 127:243-251.
53. Wang J., Della P.K., Wang H., Karczewski J., Connolly T.M., Koblan K.S., et al. Functional and pharmacological properties of canine ERG potassium channels. American Journal of Physiology - Heart and Circulatory Physiology 2003, 284:H256-H267.
54. Weerapura M., Hebert T.E., Nattel S. Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflügers Archiv 2002, 443:520-531.
55. Weerapura M., Nattel S., Chartier D., Caballero R., Hebert T.E. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?. The Journal of Physiology 2002, 540:15-27.
56. Witchel H.J., Pabbathi V.K., Hofmann G., Paul A.A., Hancox J.C. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Letters 2002, 512:59-66.
57. Yao X., Anderson D.L., Ross S.A., Lang D.G., Desai B.Z., Cooper D.C., et al. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. British Journal of Pharmacology 2008, 154:1446-1456.
58. Yao J.A., Du X., Lu D., Baker R.L., Daharsh E., Atterson P. Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. Journal of Pharmacological and Toxicological Methods 2005, 52:146-153.
59. Zeng H., Penniman J.R., Kinose F., Kim D., Trepakova E.S., Malik M.G., et al. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride. Assay and Drug Development Technologies 2008, 6:235-241.
60. Zhang S., Zhou Z., Gong Q., Makielski J.C., January C.T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circulation Research 1999, 84:989-998.
61. Zhou Z., Vorperian V.R., Gong Q., Zhang S., January C.T. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. Journal of Cardiovascular Electrophysiology 1999, 10:836-843.
62. Zunkler B.J., Claassen S., Wos-Maganga M., Rustenbeck I., Holzgrabe U. Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels. Toxicology 2006, 228:239-248.